Table 1 Clinical characteristics of patients with gout or osteoarthritis
From: Neutrophil extracellular trap clearance by synovial macrophages in gout
|  | Gout (n = 25) | OA (n = 10) | P |
|---|---|---|---|
Age (years, median [IQR]) | 63 (50–78) | 62 (56–66) | 0.694 |
Male (%) | 25 (100%) | 4 (40.0%) | <  0.001 |
CRP (mg/dL, median [IQR]) | 12.08 (4.44–17.75) | 0.22 (0.10–1.00) | <  0.001 |
Uric acid (mg/dL, median [IQR]) | 6.0 (5.1–9.3) | 5.0 (4.1–6.7) | 0.137 |
Involved joint | |||
 Knee | 24 (96.0%) | 10 (100%) | 1.000 |
 Ankle | 8 (32.0%) | 1 (10.0%) | 0.234 |
 Foot | 5 (20.0%) | 0 (0%) | 0.291 |
Treatment | |||
 IA steroid | 19 (76.0%) | 3 (30.0%) | 0.019 |
 Systemic steroid | 11 (44.0%) | 1 (10.0%) | 0.112 |
 NSAIDs | 9 (36.0%) | 7 (70.0%) | 0.131 |
Urate-lowering therapy | |||
 Allopurinol | 2 (8.0%) | 0 (0%) | 0.579 |
 Febuxostat | 6 (24.0%) | 0 (0%) | 0.151 |
Joint fluid analysis | |||
 WBCs (/μL, median [IQR]) | 33,500 (20750–53,955) | 150 (74–554) | <  0.001 |
 Neutrophil (/μL, median [IQR]) | 28,800 (18184–49,206) | 2 (0–19) | <  0.001 |